The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1269-1276

  Tauchi, Tetsuzo ^a   Okabe, Seiichi ^a   Miyazawa, Keisuke ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

BCR ABL; Ras activation; Tetramerization domain

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CARCINOGENICITY; COMPLEX FORMATION; DELETION MUTANT; FEMALE; GENE ACTIVATION; HEMATOPOIETIC CELL; LEUKEMIA; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0031839231     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1269     Document Type: Article

References (34)

1. Heiterkamp N, Stam K and Groffen J: Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 315: 758-761, 1985.
2. Tauchi T and Broxmeyer HE: BCR/ABL signal transduction. Int J Hematol 61: 105-112, 1995.
3. Konopka JB, Watanabe SM and Witte ON: An alternation of the human c-Abl protein in K562 leukemia cells unmasks associated kinase activity. Cell 37: 1035-1042, 1984.
4. Kloetzer W, Kurzrock R, Smith L, Talpatz M, Speller M, Gulterman J and Arlinghaus R: The human cellular Abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140: 230-238, 1985.
5. Young JC and Witte ON: Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long term lymphoid or myeloid culture. Mol Cell Biol 8: 4079-4087, 1988.
6. Daley GQ, Van Etten RA and Baltimore D: Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 85: 9312-9316, 1988.
7. Daley GQ, Van Etten RA and Baltimore D: Introduction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of Philadelphia chromosome. Science 247: 824-830, 1990.
8. Mandanas RA, Leibowitz DS, Gharenbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN and Boswell HS: The role of p21ras in p210bcr-abl transformation of murine myeloid cells. Blood 82: 1838-1847, 1993.
9. Sawyers CL, MacLaughlin J and Witte ON: Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene. J Exp Med 181: 307-313, 1995.
10. Cortez D, Kadlec L and Pendergast AM: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15: 5531-5541, 1995.
11. Goga A, McLaughlin J, Afar DEH, Saffran DC and Witte ON: Alternative signals to Ras for hematopoietic transformation by the BCR-ABL oncogene. Cell 82: 981-988, 1995.
12. Gishizky M, Cortez D and Pendergast AM: Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 92: 10889-10893, 1995.
13. Pendergast AM, Quillian LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J and Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb2 adaptor protein. Cell 75: 175-185, 1993.
14. Tauchi T, Boswell HS, Leibowitz DS and Broxmeyer HE: Coupling between p210bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor-independent link to Ras activation pathway. J Exp Med 179: 167-175, 1994.
15. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R and Pawson T: BCR-ABL oncoproteins bind directly to activators of Ras signaling pathway. EMBO J 13: 764-773, 1994.
16. Tauchi T, Feng GS, Shen R, Song HY, Donner D, Pawson T and Broxmeyer HE: SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem 269: 15381-15387, 1994.
17. Ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N and Groffen J: Cellular interactions of CRKL, an SH2-SH3 adaptor protein. Cancer Res 54: 2563-2567, 1994.
18. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD and Druker BJ: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269: 22925-22928, 1994.
19. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B and Griffin JD: Tyrosine phosphorylation of vav in myeloid cells is regulated by granulocyte macrophage colony stimulating factor, interleukin-3 and steel factor and is constitutively increased by p210bcr-abl. EMBO J 14: 257-265, 1995.
20. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T and Griffin JD: Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 79: 2215-2220, 1992.
21. McWhirter JR and Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-ABL by bcr sequence in BCR/ABL fusion proteins. Mol Cell Biol 11: 1553-1565, 1991.
22. McWhirter JR, Galasso DL and Wang JYJ: A coiled-coil oligomerization domain of bcr is essential for the transforming function of BCR-ABL oncoprotein. Mol Cell Biol 13: 7587-7595, 1993.
23. McWhirter JR and Wang JYJ: An actin-binding function contributes to transformation by the BCR-ABL oncoprotein of Philadelphia chromosome-positive human leukemia. EMBO J 12: 1533-1546, 1993.
24. Afar DEH, Goga A, McLaughlin J, Witte ON and Sawyers CL: Differential complementation of BCR/ABL point mutants with c-myc. Science 264: 424-426, 1994.
25. Renshaw MW, McWhirter JR and Wang JYJ: The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 15: 1286-1293, 1995.
26. Feinstein E, Cimio G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A and Canaani E: Nucleotide sequence analysis of human c-abl and bcr-abl c-DNA. Oncogene 4: 1477-1481, 1991.
27. Tauchi T, Feng GS, Marshall MS, Shen R, Mantel C, Pawson T and Broxmeyer HE: The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. J Biol Chem 269: 25206-25211, 1994.
28. Zhang XF, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Eclledge SJ, Marshall MS, Bruder JT, Rapp UR and Avruch J: Normal and oncogenic p21ras proteins bind to the amino-terminal reguratory domain of c-Raf-1. Nature 364: 308-313, 1993.
29. Hallberg B, Rayter SI and Downward J: Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem 269: 3913-3916, 1994.
30. McLaughlin J, Chianese E and Witte ON: Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 9: 1866-1874, 1989.
31. Lugo TG, Pendergast AM, Muller AJ and Witte ON: Tyrosine kinase activity and transforming potency of bcr-abl oncogene product. Science 247: 1079-1082, 1990.
32. Muller AJ, Young JC, Pendergast AM, Podel M, Landau RN, Littman DR and Witte ON: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemia. Mol Cell Biol 11: 1785-1792, 1991.
33. Soler C, Alvarez CV, Beguinot L and Carpenter G: Potent SHC tyrosine phosphorylation by epidermal growth factor at low receptor density or in the absence of receptor auto-phosphorylation site. Oncogene 9: 2207-2215, 1994.
34. Tauchi T, Miyazawa K, Feng GS, Broxmeyer HE and Toyama K: A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. J Biol Chem 272: 1389-1394, 1997.